KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kymera Therapeutics Inc (KYMR) is not a strong buy for a beginner, long-term investor at the moment. While the company has shown significant growth in its stock price over the past year and has positive sentiment from major institutional investors like Baker Bros. Advisors, the financial performance is weak, with declining revenue and negative gross margins. Additionally, insider selling and overbought technical indicators suggest caution. The absence of strong proprietary trading signals also does not support an immediate buy decision.
The stock is in a bullish trend with MACD positively expanding and moving averages indicating upward momentum (SMA_5 > SMA_20 > SMA_200). However, RSI at 90.608 signals the stock is overbought, suggesting a potential pullback. Key resistance levels are at R1: 93.868 and R2: 97.536, while support levels are at S1: 81.996 and S2: 78.328.
["Baker Bros. Advisors increased their stake by purchasing 2,005,813 shares valued at $135.45 million.", "The company has a strong cash position of $1.6 billion and has established new partnerships.", "Analysts have raised price targets significantly after positive Phase 1b data for KT-621 in atopic dermatitis."]
["Insiders are selling heavily, with a 683.38% increase in selling activity over the past month.", "Wolfe Research downgraded the stock to Peer Perform, citing valuation concerns and lack of catalysts.", "The stock is overbought based on RSI, and technical indicators suggest a potential pullback."]
In Q4 2025, revenue dropped by 61.18% YoY to $2.87 million, gross margin fell to 0%, and net income improved slightly but remained negative at -$86.98 million. EPS increased to -0.97, up 10.23% YoY.
Analyst sentiment is mixed. Barclays recently assumed coverage with an Overweight rating and raised the price target to $133, citing undervaluation and strong fundamentals in the biotech sector. However, Wolfe Research downgraded the stock, citing valuation concerns and lack of near-term catalysts. Other analysts have raised price targets significantly following positive Phase 1b data for KT-621.
